Clinical trials

The purpose of this study is to evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

The major diseases affecting thoracic aorta are aortic aneurysms and acute aortic dissections. The natural history of ascending thoracic aortic aneurysms is to asymptomatically enlarge over time until a tear in the intimal layer leads to an ascending aortic dissection. With dissection, blood penetrates into the aortic wall and separates the aortic layers, causing aortic rupture and other complications. The Montalcino Aortic Consortium (MAC) will provide the infrastructure to assemble large cohorts of patients with heritable thoracic aortic disease (H-TAD) with causal mutations in the known H-TAD genes and better define the natural and clinical history and phenotypic features associated with mutations of these genes as well as examine genetic and environmental modifiers and other biomarkers of H-TAD

Phase II objective is to compare the treatment effect of the combination of fianlimab and cemiplimab to cemiplimab alone as peri-operative therapy in patients with resectable melanoma.
Phase III objective is to assess the EFS for the combination of fianlimab and cemiplimab vs pembrolizumab alone as peri-operative therapy in patients with resectable melanoma. 

An Open-label, Randomized, Controlled Phase III Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

NN7535-7807 A global phase III, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease

A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial)

The purpose of this study is to compare the effects of two anticancer drugs (amivantamab and cetuximab) when each is given in combination with standard colorectal cancer (CRC) chemotherapy (FOLFIRI, mFOLFOX6) to participants with metastatic CRC that lack mutations in genes called KRAS/NRAS and BRAF. Cetuximab, FOLFIRI and mFOLFOX6 are already used to treat participants with this type of cancer.

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (RAINFOL-02)